ENLV — Enlivex Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1596812 ·
Israel
Last close
$0.60
Market Cap
$10.46M
52W High
$27.15
52W Low
$0.57
ADV30
355,000
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | — | -5,861,000 | 1,243,053,000 | 2,326,998,000 | 1,894,000 | 392,050,000 |
| Sep 2025 | 0 | — | -2,557,000 | -2,205,000 | 20,938,000 | 4,083,000 | 3,457,000 |
| Jun 2025 | 0 | — | -3,078,000 | -1,868,000 | 22,598,000 | 1,892,000 | 3,544,000 |
| Mar 2025 | 0 | — | -3,504,000 | -3,452,000 | 24,035,000 | 2,053,000 | 3,408,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-10,416,000
Investing CF
$-1,323,000
Financing CF
$10,381,000
CapEx
$-68,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.80
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$1,108,421,000
Inventory
—
Receivables
$510,000
ST Investments
$3,861,000
EBIT TTM
$-15,000,000
Pretax Income TTM
$1,618,174,000
Interest Exp TTM
—
Analysts
1
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -15,000,000 | 1,235,528,000 | 2,326,998,000 | 392,050,000 | 1,934,948,000 | -10,416,000 |
| Dec 2024 | 0 | -14,931,000 | -15,014,000 | 27,687,000 | 4,098,000 | 23,589,000 | -13,008,000 |
| Dec 2023 | 0 | -25,151,000 | -29,068,000 | 36,831,000 | 6,747,000 | 30,084,000 | -23,523,000 |
| Dec 2022 | 0 | -25,797,000 | -31,060,000 | 67,642,000 | 10,801,000 | 56,841,000 | -23,953,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.78
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AZTR | Azitra, Inc. | $10.18M | $0.17 | — |
| TOVX | Theriva Biologics, Inc. | $10.10M | $0.22 | — |
| MTVA | MetaVia Inc. | $10.94M | $1.66 | — |
| APUS | Apimeds Pharmaceuticals US, Inc. | $10.94M | $7.25 | — |
| BIOE | Bio Essence Corp | $9.79M | $0.18 | — |
News headlines (Yahoo Finance, 1h cache)
Enlivex Ltd. (ENLV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
2026-09-01 13:55 · Yahoo
Enlivex Ltd. (ENLV) Upgraded to Buy: Here's Why
2026-07-13 16:00 · Yahoo
Exclusive: FDA grants RMAT designation to Enlivex’s Allocetra for knee OA
2026-07-13 11:30 · Yahoo
Enlivex advances Allocetra while expanding into prediction markets
2026-05-11 17:39 · Yahoo
Enlivex to Present Phase IIa 3-month and 6-month Data of Allocetra at OARSI 2026 World Congress
2026-04-23 12:30 · Yahoo
H.C. Wainwright Highlight Improved Balance Sheet Supporting Enlivex Ltd. (ENLV) Outlook
2026-04-21 02:46 · Yahoo
Enlivex Ltd. (ENLV) Loses 31.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
2026-07-13 13:35 · Yahoo
Ondo Global Markets Tokenizes Enlivex’s Ordinary Shares
2026-04-08 12:30 · Yahoo
Enlivex Therapeutics Q4 Earnings Call Highlights
2026-03-25 14:18 · Yahoo
Off The Hook Yachts and Enlivex Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
2026-03-20 13:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.